HOME > Overseas Activity

Overseas Activity

 Over many years, Kaken has been marketing a number of its original products under license or distributorship in overseas countries. Such out-licensed products include Mentax, Empynase, Sonifilan, and Fiblast.

 Mentax is an antifungal agent launched or approved in Asian countries and the U.S.A.

 Empynase is an antiphlogistic enzyme for relief of swelling and difficulty in expectoration and on the market in Korea.

 Sonifilan is an immunomodulator to be used for the treatment of uterine cervical cancer in combination with irradiation and on the market in Korea.

 Fiblast is a spray formulation to treat skin ulcers such as bed-sore and burns. After obtaining marketing authorization, Daewoong distribute Fiblast in Korea.

Mentax ( Antifungal Drug )
COUNTRY COMPANY STATUS BRAND NAME
U.S.A. Bertek Launched Mentax
Schering-Plough HealthCare Products Launched Lotrimin Ultra(OTC)
Korea Yungjin Launched Mentax
Choongwae Shinyak Launched Butena
Israel Perrigo Launched Mentax
Taiwan Sinphar Launched Mentax
Jordan Hikma Launched Mentax
Empynase(Antiphlogistic Enzyme)
COUNTRY COMPANY STATUS BRAND NAME
Korea Yungjin Launched Empynase
Empynase-S
Dong Kwang Launched Pronase
Samjin Launched Maronase
Asia Launched Tromase
Jin Yang Launched Rosecin
Sonifilan ( Anti-tumor Drug )
COUNTRY COMPANY STATUS BRAND NAME
Korea Pharmbio Launched Sonifilan
Copyright(C) Kaken Pharmaceutical Co.,Ltd. All Rights Reserved.
Kaken Pharmaceutical Co.,Ltd. HOME Site map Contact Japanese